@article{fdi:010048337,
  title = {{S}tandardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid : a systematic review and meta-analysis},
  author = {{M}enzies, {D}. and {B}enedetti, {A}. and {P}aydar, {A}. and {R}oyce, {S}. and {P}ai, {M}. and {B}urman, {W}. and {V}ernon, {A}. and {L}ienhardt, {C}hristian},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {A} standardized regimen recommended by the {W}orld {H}ealth {O}rganization for retreatment of active tuberculosis ({TB}) is widely used, but treatment outcomes are suspected to be poor. {W}e conducted a systematic review of published evidence of treatment of patients with a history of previous treatment or documented isoniazid mono-resistance. {M}ethods and {F}indings: {P}ub{M}ed, {EMBASE}, and the {C}ochrane {C}entral database for clinical trials were searched for randomized trials in previously treated patients and/or those with with mono-resistance to isoniazid, published in {E}nglish, {F}rench, or {S}panish between 1965 and {J}une 2008. {T}he first two sources were also searched for cohort studies evaluating specifically the current retreatment regimen. {I}n studies selected for inclusion, rifampin-containing regimens were used to treat patients with bacteriologically confirmed pulmonary {TB}, in whom bacteriologically confirmed failure and/or relapse had been reported. {P}ooled cumulative incidences and 95% {CI}s of treatment outcomes were computed with random effects meta-analyses and negative binomial regression. {N}o randomized trials of the currently recommended retreatment regimen were identified. {O}nly six cohort studies were identified, in which failure rates were 18%-44% in those with isoniazid resistance. {I}n nine trials, using very different regimens in previously treated patients with mono-resistance to isoniazid, the combined failure and relapse rates ranged from 0% to over 75%. {F}rom pooled analysis of 33 trials in 1,907 patients with mono-resistance to isoniazid, lower failure, relapse, and acquired drug resistance rates were associated with longer duration of rifampin, use of streptomycin, daily therapy initially, and treatment with a greater number of effective drugs. {C}onclusions: {T}here are few published studies to support use of the current standardized retreatment regimen. {R}andomized trials of treatment of persons with isoniazid mono-resistance and/or a history of previous {TB} treatment are urgently needed.},
  keywords = {},
  booktitle = {},
  journal = {{P}los {M}edicine},
  volume = {6},
  numero = {9},
  pages = {e1000150},
  ISSN = {1549-1277},
  year = {2009},
  DOI = {10.1371/journal.pmed.1000150},
  URL = {https://www.documentation.ird.fr/hor/fdi:010048337},
}